EDTA-Induced Pseudothrombocytopenia up to 9 Months after Initial COVID-19 Infection Associated with Persistent Anti-SARS-CoV-2 IgM/IgG Seropositivity

Article Cell Biology

SARS-CoV-2 infection is associated with a pro-thrombotic platelet phenotype

Dario Bongiovanni et al.

Summary: This study found that platelets of COVID-19 patients showed increased expression of activation markers without stimulation, and further elevated expression of P-selectin when stimulated with TRAP. However, COVID-19 platelets exhibited reduced capacity to express LAMP-3 and P-selectin upon TRAP stimulation. These findings suggest a hyperactivated platelet phenotype during SARS-CoV-2 infection, potentially contributing to the observed hypercoagulopathy in COVID-19 patients.

CELL DEATH & DISEASE (2021)

添加到收藏夹

Editorial Material Hematology

Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination

Eun-Ju Lee et al.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

添加到收藏夹

Article Infectious Diseases

A dramatic rise in serum ACE2 activity in a critically ill COVID-19 patient

Bela Nagy et al.

Summary: Studies have shown that the significant increase in ACE2 activity in COVID-19 patients may be an endogenous nonspecific protective mechanism against viral infection, which could play a role before the patient's recovery.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

添加到收藏夹

Review Medicine, General & Internal

Pseudothrombocytopenia-A Review on Causes, Occurrence and Clinical Implications

Benjamin Lardinois et al.

Summary: Pseudothrombocytopenia (PTCP) is a common finding in clinical laboratories and can have serious consequences if not promptly detected. Studies suggest that PTCP incidence seems to be higher in patients receiving low molecular weight heparin, during hospitalization, or in men aged 50 years or older. New analytical technologies are expected to revolutionize traditional algorithms and provide valuable diagnostic aids.

JOURNAL OF CLINICAL MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

Nina H. Schultz et al.

Summary: This study reports five cases of venous thrombosis and thrombocytopenia occurring 7 to 10 days after receiving the ChAdOx1 nCoV-19 vaccine, suggesting a rare vaccine-induced immune thrombotic thrombocytopenia. The condition, which can lead to catastrophic outcomes such as cerebral venous sinus thrombosis, may be treated with intravenous immune globulin.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Andreas Greinacher et al.

Summary: After vaccination with ChAdOx1 nCov-19, rare immune thrombotic thrombocytopenia can occur due to platelet-activating antibodies against PF4, resulting in various thrombotic events. Most patients in this case series were women, with fatal outcomes such as cerebral venous thrombosis and intracranial hemorrhage. Additional studies are needed to further investigate and understand this phenomenon.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Cell Biology